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CLINICAL STUDY
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Abstract
OBJECTIVE: To observe effect of compound Kush-
en injection on T-cell subgroups and NK cells in pa-
tients with locally advanced non-small-cell lung
cancer (NSCLC) treated with concomitant radioche-
motherapy.
METHODS: We randomly divided 60 patients with
locally advanced NSCLC who were treated at our
hospital between May 2011 and May 2013 into a
treatment group and a control group by drawing.
The treatment group (n = 30) received concomitant
radiochemotherapy plus compound Keshen injec-
tion, and the control group (n = 30) received only
radiochemotherapy.
RESULTS: After treatment, levels of CD3+ , CD4+ ,
CD4 +/CD8 + and CD16 +/CD56 + cells had signifi-
cantly increased, and CD8+ cells had significantly
decreased, in the treatment group compared with
both their pretreatment levels and with levels in
the control group. In the control group, post-treat-
ment levels of CD3 + , CD4 + , CD4 +/CD8 + and
CD16+/CD56+ cells were not significantly changed
from pretreatment levels. The two groups did not
significantly differ in their rates of toxicity reactions
(P > 0.05).
CONCLUSION: Compound Kushen injections can
increase immunologic function in patients with lo-
cally advanced non-small cell lung cancer who re-
ceive concomitant radiochemotherapy.
© 2016 JTCM.
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INTRODUCTION
Patients with non-small cell lung cancer (NSCLC) ac-
count for about 80% of patients with lung cancer.
Among them, locally advanced NSCLC (LA-NSCLC)
accounts for 40%-50% of NSCLC.1 For LA-NSCLC,
successful excision is less probable, and concomitant ra-
diochemotherapy (CRCT) is the primary treatment at
present. However, compared with single-mode radio-
therapy or chemotherapy, CRCT increases toxicity and
decreases immunologic function, leading to decreased
tolerance that may curtail treatment in severe cases.2
Traditional Chinese Medicine holds that in treating tu-
mors, eliminating pathogenic factors and strengthen-
ing genuine Qi are of equal importance; eliminating
pathogenic factors is killing tumor cells by using radio-
therapy or chemotherapy, and strengthening genuine
Qi protects immunologic functions of the organism by
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using drugs, increasing immunity of the organism.3,4
Clinically, Chinese drugs with functions of strengthen-
ing genuine Qi to consolidate the constitution, promot-
ing blood circulation to remove blood stasis, and clear-
ing heat and removing toxic substance are more used
for strengthening genuine Qi at present. Compound
Kushen injection (CKI) is made from the extract of
Kushen (Radix Sophorae Flavescentis) and Tufuling (Rhi-
zoma Smilacis Chinae), containing the chemical compo-
nents such as oxymatrine, matrine, sophocarpine, soph-
orine, sophoridine, and kurarinone.5 Modern study in-
dicates that CKI has many pharmacologic properties,
such as anti-tumor, anti-inflammation, analgesia, and
immunity-enhancing activity, and is widely used for ac-
cessory treatment of cancers including that of the diges-
tive tract, NSCLC, and primary liver cancer. Since Jan-
uary 2011, our department has used CKI to increase
immunity of patients with LA-NSCLC with CRCT,
achieving a good clinical therapeutic effect, as reported
in the following.
MATERIALS ANDMETHODS
Clinical data
We selected 60 patients (32 men and 28 women) with
LA-NSCLC who were treated at our hospital between
May 2011 and May 2013. They were assigned to a
treatment group or a control group (n = 30 for both),
by using a random drawing. This experimental study
was approved by the Ethics Committee of the Hospi-
tal. All of the patients provided signed informed con-
sent forms.
Inclusion criteria
We included patients for whom (a) NSCLC was estab-
lished as adenocarcinoma or squamous carcinoma, by
pathological or cytological detection after aspiration bi-
opsy; (b) the patient had phase Ⅲ a or Ⅲ b disease
(IASLC2009 staging criteria); 6 (c) The patients had
not received previous radiotherapy or chemotherapy;
(d) patient's Karnofsky performance score (KPS) ≥ 70,
and predicted living time ≥ a half year; (e) electrocar-
diogram, routine blood tests and liver function and re-
nal function were normal; and (f ) the patient provided
informed consent.
Exclusion criteria
We excluded patients who had (a) obvious pulmonary
emphysema or respiratory function decompensation,
(b) autoimmune disease, or (c) phase IIIa disease that
required surgery.
Treatment methods
Both the control and treatment groups received 3-di-
mensional conformal radiation therapy (3D-CRT)
with a concomitant regimen of duoxitasai + cisplatin
(DP). The treatment group received CKIs at the same
time.
For the 3D-CRT: The body position was fixed with a
body model, with Toziba 16-row CT modeling loca-
tion and scanning layer thickness 5 mm, and the figure
was transferred into the planning system (3DTPS).
Clinical target area volume (CTV) included the prima-
ry focus of the lung, the hilus of lung of the same side
and the draining area of mediastinal lymph nodes. The
margin was 0.6-0.8 cm outside the tumor volume
(GTV), shown by the lung window in the CT slice.
The planned target volume (PTV) was extra-spreading
0.8-1.5 cm on the basis of CTV; 95% of the isodose
curve covered the PTV, with lung dose: V20 ≤ 20% ;
heart: ≤ 30 Gy; spinal cord: ≤ 40 Gy. Patients received
6MV-X radiation therapy at 4-6 conformal visual
fields, 2.0 Gy/f, 1 f/d, 5 f/w; after the tissue dosage
reached to 40 Gy/4 w, chest CTs were rechecked. Ac-
cording to any changes of the focus, the primary focus
was then radiated with DT 60-70 Gy over the reduced
area.
The DP (duoxitasai +cisplatin) regimen was Duoxitasai
(Jiangsu Hengrui Medical Limited Company, Batch
No. H20031227, Lianyungang, China) 20 mg/m2, in-
travenous drip, on the first day; cisplatin (Jiangsu Ha-
oshen Pharmacy Limited Company, Batch No.
H20050563, Lianyungang, China) 30 mg/m2, intrave-
nous drip on the first day. The chemotherapy was con-
comitantly carried out on the first day of radiotherapy,
once a week, until the end of radiotherapy. During che-
motherapy, patients received treatments for inhibiting
acid and nausea, and protecting the liver.
In the treatment group, at the beginning of radioche-
motherapy, compound Kushen injection (Shanxi Zhen-
dong Pharmacy Limited Company, Chinese medicine
permit No. Z14021231) 20 mL plus 200 mL saline
was given, intravenous drip, at 40-60 drips each min,
once a day for 15 days.
Observation indices
Patients' peripheral blood T-lymphocyte subgroups
(CD3+, CD4+, CD8+) and natural killer (NK) cells
(CD16+, CD56+) were detected with a flow cytometry
one day before treatment and one week after the end of
the treatment in both groups. Ratios of CD4+/CD8+
were calculated.
Statistical analysis
Statistical analysis was carried out with SPSS13.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Data were ex-
pressed as mean ± standard deviation ( xˉ ± s). Indepen-
dent sample t-tests were used to compare the two
groups. Toxicity reactions in the two groups were com-
pared with χ2 tests. P < 0.05 was considered signifi-
cance.
RESULTS
Comparison of basic data of the patients
At last, 60 patients (32 men and 28 women) with
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LA-NSCLC were included in our study. Thirty pa-
tients were assigned in treatment group and control
group, respectively. The two groups did not significant-
ly differ in clinicopathological informations (P > 0.05,
Table 1).
Changes of T-cell subgroups and NK cells
One day before treatment, the treatment and control
groups did not significantly differ in the peripheral
blood counts for CD3+, CD4+, CD8+, CD4+/CD8+
cells or NK cells (CD16+/CD56+ ) (P > 0.05). After
the end of treatment, levels of CD3+, CD4+, CD4+/
CD8+ and CD16+/CD56+ cells increased and CD8+
cells decreased significantly in the treatment group (Fig-
ures 1-3), compared with both their pretreatment lev-
els and levels in the control group (both P < 0.05), which
Item
Sex
Age
KPS
Pathological type
TNM phase
Male
Female
< 60 years
≥ 60 years
70-90
≥ 90
Squamous carcinoma
Adenocarcinoma
Ⅲa
Ⅲb
Treatment group (n = 30)
18
12
17
13
16
14
15
15
16
14
Control group (n = 30)
14
16
11
19
19
11
17
13
12
18
χ2 value
1.071
2.411
0.625
0.268
1.071
P value
0.301
0.121
0.732
0.605
0.301
Table 1 Comparison of general data between the treatment group and the control group (n)
Notes: both the control and treatment groups received 3D-CRT with a concomitant regimen of DP. Differently, the treatment group re-
ceived CKIs at the same time. KPS: Karnofsky performance score; TNM: TNM staging; 3D-CRT: 3-dimensional conformal radiation ther-
apy; CKIs: compound Kushen injection; DP: duoxitasai +cisplatin.
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Figure 2 Changes of CD4+ and CD8+ counts in the peripheral blood of the treatment group
A: before treatment; B: after treatment.
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Figure 1 Change of CD3+ count in the peripheral blood of the treatment group
A: before treatment; B: after treatment.
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implies that immunologic function in patients with
LA-NSCLC with CRCT after CKI significantly im-
proved. In the control group, pre- and post-treatment
CD3+, CD4+, CD4+/CD8+ and CD16+CD56+ lev-
els did not significantly differ (P > 0.05; Table 2).
Toxicity reactions
Toxicity reactions were assigned scores of Ⅰ-Ⅳ in
both the treatment and control groups. Among them,
decreased white cells were scored as grade I: 3.0- < 4.0
× 109/L; gradeⅡ: 2.0-2.9 × 109/L; gradeⅢ: 1.0-119 ×
109/L; and grade Ⅳ: < 1.0 × 109/L. Hemoglobin de-
crease was scored as grade I: 95-109 g/L; grade Ⅱ:
80-95 g/L; gradeⅢ: 65-79 g/L; and gradeⅣ: < 65 g/L.
Blood creatinine levels > 133 μmol/L were considered
to indicate injured renal function. Transaminase activi-
ty above 40 U/L was considered to indicate injured liv-
er function. The two groups did not significantly differ
in toxicity incidence rates (Table 3). In the treatment
group, one patient had fever after CKI (highest body
temperature: 38.1 ℃ ); after symptomatic treatment,
his temperature returned to normal, with no allergy
and other adverse responses, and no treatment-related
death.
DISCUSSION
As CRCT can improve the survival time for
LA-NSCLC,7 it has been become a standard treatment
program for middle-late NSCLC.8 However, radiother-
apy and chemotherapy can not avoid injury to the im-
mune system, which mainly manifests in the following
two aspects: radioactivity has a directly cytotoxic action
on immune effector cells, and the drugs of chemothera-
py can directly or indirectly kill immunologic effector
cells, both leading to decreased immune function.9,10
Thus, protecting immune functions of patients with
LA-NSCLC is a consideration in CRCT.
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Figure 3 Change of NK cell count in the peripheral blood of the treatment group
A: before treatment; B: after treatment.
Group
Treatment
Control
n
30
30
Nausea, vomiting
17 (56.7)
19 (63.3)
Leukopenia
14 (46.7)
13 (43.3)
Anemia
10 (33.3)
11 (36.7)
Radiation
pneumonia
2 (6.7)
1 (3.3)
Impairment
of renal function
0 (0.0)
2 (6.7)
Impairment
of liver function
3 (10.0)
4 (13.3)
Table 3 Comparison of toxicity incidence rates between the treatment and control groups [n (%)]
Notes: both the control and treatment groups received 3-dimensional conformal radiation therapy with a concomitant regimen of duoxita-
sai +cisplatin. Differently, the treatment group received compound Kushen injection at the same time.
Group
Treatment
Control
Before treatment
After treatment
Before treatment
After treatment
n
30
30
30
30
CD3+
62.9±3.1
72.2±3.0ab
62.9±2.6
62.1±1.3c
CD4+
31.4±4.3
38.2±2.3ab
32.9±4.1
32.3±2.1c
CD8+
31.1±5.2
22.2±1.0b
32.0±5.0
32.0±3.5c
CD4+/CD8+
1.0±0.8
1.7±22ab
1.0±0.8
1.0±0.6c
CD16+/CD56+
11.4±1.4
18.1±0.7ab
12.1±1.1
12.0±2.6c
Notes: both the control and treatment groups received 3-dimensional conformal radiation therapy with a concomitant regimen of duoxita-
sai+cisplatin. Differently, the treatment group received compound Kushen injection at the same time. Two dependent sample t-tests were
used, compared with the control group after treatment, aP < 0.05. Paired t-test was used, compared with the treatment group before treat-
ment, bP < 0.05; compared with the control group before treatment, cP > 0.05.
Table 2 Comparison of T-cell subgroups and NK cells in the treatment and control groups before and after treatment (%, xˉ ± s)
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The combination of CKI with cyclophosphamide can
promote transformation of T lymphocytes, improve
maladjustment of CD4+/CD8+ ratio, strengthen activi-
ty and improve the NK killing rate.11 Dong et al 12 treat-
ed 40 patients with advanced NSCLC using CKI with
a PD (duoxitasai + cisplatin) chemotherapy regimen;
they found the ratio of T cell subgroups and NK cells
significantly improved, increasing patients' immunolog-
ic function. Hong et al 13 randomly divided 50 patients
with middle-late lung adenocarcinoma into a CKI plus
chemotherapy group (treatment group) and a chemo-
therapy-only group (control group). The percentage of
CD4 + were 39.7% ± 1.7% in treatment group and
31.5% ± 1.4% in control group after treating (P <
0.001). And percentage of CD8+ were 27.8% ± 1.3%
in treatment group and 24.3% ± 1.6% in control
group (P < 0.001). Research results of Luo14 were simi-
lar to the results ofDong et al 12 and Hong et al.13 Howev-
er, at present, reports on the use of CKI in patients
treated with LA-NSCLC with CRCT was not found.
Therefore, this study was very nessary to carry out.
Anti-tumor immune responses are T cell-mediated spe-
cific anti-tumor immune response. T cells can be divid-
ed into CD4+ helper/ induced T cells, CD8+ suppres-
sor /killer T cells, at CD4 +/CD8 + ratio of 1.5-2.0.
When immunologic function in cancer patients is in-
jured, CD4+ cells will decrease, CD8+ cells increase,
and the CD4+/CD8+ decrease, or even invert.15 CD3+
can reflect the total levels of CD4 and CD8. CD16
and CD56 are surface markers of NK cells; when cellu-
lar immunologic function decreases, the ratio of NK
cells will also decrease, unable to effectively kill tumor
cells. Therefore, determination of changes of peripheral
blood T cell subgroups and NK cells with flow cytome-
ter can show changes of immunologic function.
In the present study, after the end of CRCT, T-cell sub-
groups and NK cells decreased somewhat in the con-
trol group patients compared with their pretreatment
levels, indicating that radiochemotherapy has an inhibi-
tory action on immunologic function; whereas among
patients in the treatment group, T cell subgroups
(CD3+, CD4+, CD4+/CD8+) and NK cells (CD16+
CD56 + ) significantly increased, which suggests that
their immunologic function improved, which is similar
to previous research results. Although CKI can increase
immunologic function of the patient, whether it can
prolong the survival of patients with LA- NSCLC treat-
ed with CRCT needs further investigation.
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